Crude incidence rates and risk of ASCVD in patients with RA by unprovoked VTE
| Events/patients | % | Patient-years | Incidence rate (95% CI)* | Unadjusted HR (95% CI) | Adjusted HR for age, sex and year (95% CI) | Adjusted HR (95% CI)† | |
| Patients without prior VTE or ASCVD | 1283/25 070 | 5.1 | 147 735 | 8.68 (8.22 to 9.17) | – | – | – |
| Patients with first unprovoked VTE (no prior ASCVD or VTE) | 38/506 | 7.5 | 16 152 | 23.53 (17.12 to 32.33) | 2.50 (1.81 to 3.44) | 2.32 (1.69 to 3.11) | 2.05 (1.43 to 2.95) |
| Deep venous thrombosis | 21/325 | 6.5 | 11 150 | 18.83 (12.28 to 28.87) | 2.03 (1.32 to 3.12) | 2.00 (1.39 to 3.09) | 1.93 (1.22 to 3.06) |
| Pulmonary emboli | 17/181 | 9.4 | 5002 | 33.99 (21.13 to 54.67) | 3.78 (2.50 to 5.70) | 2.98 (1.92 to 4.89) | 2.52 (1.57 to 4.04) |
*Per 1000 patient-years.
†Adjusted for age; sex; disease duration; socioeconomic status (annual income, insurance and location of residency); ethnicity; smoking; hypertension; diabetes; chronic kidney disease; comorbidity index; body mass index; Health Assessment Questionnaire; patient global and pain scores; glucocorticoid use disease-modifying antirheumatic drugs (DMARDs) including methotrexate, hydroxychloroquine, tumour necrosis factor-α inhibitor (TNFi) and non-TNFi biological DMARDs (bDMARDs); non-steroidal anti-inflammatory drugs; statins; fracture; pulmonary disease; prior count of conventional synthetic DMARDs (csDMARDs) and bDMARDs; and calendar year.
ASCVD, atherosclerotic cardiovascular disease; RA, rheumatoid arthritis; VTE, venous thromboembolism.